» Articles » PMID: 34532023

Hydrogen-rich Water and Caffeine for Alertness and Brain Metabolism in Sleep-deprived Habitual Coffee Drinkers

Overview
Journal Food Sci Nutr
Specialty Biotechnology
Date 2021 Sep 17
PMID 34532023
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The main aim of this randomized-controlled cross-over interventional trial was to assess the acute effects of taking a single dose of hydrogen-rich water (HRW), and compare it with caffeine, HRW plus caffeine, and control water, for alertness, brain metabolism, brain and oxygen saturation, and self-reported adverse events in healthy men and women who were habitual coffee drinkers and were sleep-deprived for 24 hr. Sixteen apparently healthy young adults (8 men and 8 women; age 24.0 ± 3.5 years) were allocated in a cross-over design to receive a single-dose drink of HRW (8 ppm), caffeine (50 mg), HRW plus caffeine, or control drink (tap water) in the morning after 24-hr sleep deprivation and 12-hr fasting. The primary and secondary outcomes were assessed at baseline (pre-intervention) and 15-min follow-up. Significantly less time was needed to complete trail-making test after both HRW and HRW plus caffeine compared with the control drink ( < .05). The number of errors in the symbol digit modalities test was significantly lower after drinking HRW or caffeine than control drink ( < .05). Both HRW and caffeine significantly increased the choline-to-creatine ratio in several brain regions (frontal white and gray matter), while HRW and the combination intervention also affected brain metabolism in the paracentral brain. No participants reported any side effects from any intervention. The attention enhancement driven by HRW appears along with changes in brain metabolism. Being generally recognized as a safe intervention, hydrogen could be thus recommended as a novel intervention that upholds attention in stressed conditions, with its metabolic footprint likely different from caffeine.

Citing Articles

The Effect of 14-Day Consumption of Hydrogen-Rich Water Alleviates Fatigue but Does Not Ameliorate Dyspnea in Long-COVID Patients: A Pilot, Single-Blind, and Randomized, Controlled Trial.

Tan Y, Xie Y, Dong G, Yin M, Shang Z, Zhou K Nutrients. 2024; 16(10).

PMID: 38794767 PMC: 11123997. DOI: 10.3390/nu16101529.


Hydrogen-rich water improves sleep consolidation and enhances forebrain neuronal activation in mice.

Vincent S, Madani M, Dikeman D, Golden K, Crocker N, Jackson C Sleep Adv. 2024; 5(1):zpad057.

PMID: 38264142 PMC: 10803172. DOI: 10.1093/sleepadvances/zpad057.


Molecular hydrogen as an adjuvant therapy may be associated with increased oxygen saturation and improved exercise tolerance in a COVID-19 patient.

Singh R, Halabi G, Fatima G, Rai R, Tarnava A, LeBaron T Clin Case Rep. 2021; 9(11):e05039.

PMID: 34765212 PMC: 8572338. DOI: 10.1002/ccr3.5039.


Hydrogen-rich water and caffeine for alertness and brain metabolism in sleep-deprived habitual coffee drinkers.

Todorovic N, Zanini D, Stajer V, Korovljev D, Ostojic J, Ostojic S Food Sci Nutr. 2021; 9(9):5139-5145.

PMID: 34532023 PMC: 8441318. DOI: 10.1002/fsn3.2480.

References
1.
Heatherley S . Caffeine withdrawal, sleepiness, and driving performance: what does the research really tell us?. Nutr Neurosci. 2011; 14(3):89-95. DOI: 10.1179/147683011X13019262348785. View

2.
Yang M, Dong Y, He Q, Zhu P, Zhuang Q, Shen J . Hydrogen: A Novel Option in Human Disease Treatment. Oxid Med Cell Longev. 2020; 2020:8384742. PMC: 7495244. DOI: 10.1155/2020/8384742. View

3.
Srivastava S, Donaldson L, Rai D, Melichar J, Potokar J . Single bright light exposure decreases sweet taste threshold in healthy volunteers. J Psychopharmacol. 2013; 27(10):921-9. DOI: 10.1177/0269881113499206. View

4.
Iketani M, Ohsawa I . Molecular Hydrogen as a Neuroprotective Agent. Curr Neuropharmacol. 2016; 15(2):324-331. PMC: 5412697. DOI: 10.2174/1570159x14666160607205417. View

5.
Yoritaka A, Takanashi M, Hirayama M, Nakahara T, Ohta S, Hattori N . Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial. Mov Disord. 2013; 28(6):836-9. DOI: 10.1002/mds.25375. View